Padova

• A study to evaluate Samyr effectiveness and safety profile. The study is done by comparing that Samyr injection is better than placebo injec … Recruiting
  2024-513022-29-00 5 2019-01-09 Major Depression Disorders
• Extension Study for Participants in Studies That Include Pembrolizumab Recruiting
  2022-501254-10-00 5 2018-08-24 Advanced tumors
• Study in which all the patients take the same investigational drug with the aim of evaluate the long-term safety, tolerability, and efficacy … Recruiting
  2023-504520-26-00 5 2017-10-19 Duchenne Muscular Dystrophy (DMD)
• rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting
  2024-516078-31-00 10 2015-05-05 Recurrent and Primary Refractory Ewing Sarcoma
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons with HIV-1 (INNOVATE Study) Ended recruitment
  2025-521918-26-00 4 2026-02-11 HIV Infections
• A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou … Ended recruitment
  2025-522598-12-00 10 2025-12-17 Untreated Metastatic Pancreatic Ductal Adenocarcinoma
• Efficacy and safety of Silycus® in Cushing’s disease: a multicenter, single arm, open label, dose titration, proof of concept study (Silycus … Ended recruitment
  2024-518869-99-00 4 2025-11-17 Cushing's disease
• Study of BLU-808 in Chronic Inducible Urticaria and Chronic Spontaneous Urticaria Ended recruitment
  2024-520031-33-00 4 2025-09-16 Chronic Inducible Urticaria and Chronic Spontaneous Urticaria
• A Study to Compare Risankizumab to Vedolizumab in Adult Subjects With Moderate to Severe Ulcerative Colitis Ended recruitment
  2024-518998-33-00 5 2025-07-23 Ulcerative Colitis
• A Phase 2 Study of CAL101 in Patients with Idiopathic Pulmonary Fibrosis Ended recruitment
  2024-518339-12-00 4 2025-07-08 Idiopathic Pulmonary Fibrosis
• Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended recruitment
  2024-517817-34-00 9 2025-06-18 Gastric Cancer
• Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell … Ended recruitment
  2023-509067-24-01 4 2025-06-17 - Small Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment
• Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended recruitment
  2024-517818-15-00 9 2025-06-06 Non-Small Cell Lung Cancer
• A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr … Ended recruitment
  2024-511754-41-00 4 2025-05-29 idiopathic pulmonary fibrosis
• A randomised, double-blind, placebo-controlled, two-part study to evaluate the pharmacokinetics, safety and tolerability, and preliminary ef … Ended recruitment
  2024-515907-20-00 9 2025-05-23 Primary biliary cholangitis (PBC)
• A Phase 3 study to assess the efficacy, safety, and tolerability of itepekimab (anti­IL­33 mAb) in participants with inadequately-controlled … Ended recruitment
  2024-516814-39-00 5 2025-05-20 Chronic rhinosinusitis with nasal polyps
• A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended recruitment
  2024-512925-95-00 5 2025-05-16 Advanced/Metastatic Breast Cancer
• Phase 2 Study of CVN424 Ended recruitment
  2024-516811-25-00 4 2025-05-15 Parkinson Disease
• A study to investigate the effect and safety of BW-20805 in adult participants with hereditary angioedema Ended recruitment
  2024-518207-22-00 4 2025-05-15 Hereditary Angioedema
• Phase 3 study of RMC-6236 in patients with previously treated metastatic PDAC Ended recruitment
  2024-516063-89-00 5 2025-04-10 Metastatic Pancreatic Ductal Adenocarcinoma
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma Ended recruitment
  2024-513738-39-00 9 2025-03-18 IDH1-mutant Glioma
• Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended recruitment
  2024-512180-31-00 4 2025-03-14 Oligometastatic renal cell carcinoma

Showing 409–432 of 769 trials